The World Asthma Foundation’s symposium continues to shed light on airway mycosis, an often-overlooked factor in severe asthma. On Day 2, Dr. David Corry delivered a compelling presentation that delved into the latest research, diagnostic challenges, and potential treatment strategies for fungal-related lung diseases.
Why Airway Mycosis Matters
Airway mycosis refers to fungal infections and colonization in the respiratory tract, which can significantly impact asthma severity and overall lung health. Despite its potential to worsen symptoms, increase hospitalizations, and complicate treatment, it remains underdiagnosed due to limited awareness and inadequate testing methods
.
Dr. Corry’s research highlights the growing recognition of fungi as key players in respiratory diseases, emphasizing the need for more precise detection, treatment, and management strategies.
Advancing Diagnostics: A Game-Changer
One of the most pressing issues in diagnosing airway mycosis is the lack of standardized testing protocols. Dr. Corry introduced an open-source, cost-effective culturing technique that has the potential to revolutionize fungal detection. Unlike traditional methods that often fail to identify the presence of fungi, his approach allows for more accurate and reliable diagnosis.
However, regulatory hurdles remain a challenge. While these new diagnostic techniques are promising, widespread clinical adoption requires changes in how fungal infections are perceived and tested in mainstream medicine.
The Way Forward: Solutions for a Neglected Condition
Dr. Corry’s insights highlight several critical steps needed to improve outcomes for patients suffering from airway mycosis:
Raising Awareness – Educating healthcare providers and the public about fungal-related lung diseases can lead to earlier diagnosis and better treatment strategies. The World Asthma Foundation symposium is playing a key role in fostering this conversation.
Enhanced Diagnostics – With improved culturing techniques and new testing protocols, diagnosing airway mycosis can become more accessible and reliable. However, regulatory bodies must be open to adopting these innovations.
Investment in Research – There is an urgent need for more research into the mechanisms, risk factors, and treatment options for airway mycosis. The symposium serves as a catalyst for collaboration among researchers, clinicians, and industry leaders.
Conclusion
Airway mycosis represents a hidden yet significant burden on patients and healthcare systems. Dr. Corry’s presentation underscores the urgency of better diagnostics, increased research, and enhanced clinical awareness to tackle this neglected issue.
By advocating for change, supporting innovative research, and fostering global collaboration, the World Asthma Foundation is leading the charge in addressing airway mycosis.
Stay tuned for more insights from the symposium as we continue to explore the evolving landscape of asthma and respiratory health.
Millions of severe asthma sufferers are searching for answers, often unaware that airway mycosis—a hidden fungal infection—could be the underlying cause of their chronic respiratory problems. April 5-6, 2025 the World Asthma Foundation is hosting a groundbreaking symposium to explore this critical issue, bringing together experts to shed light on the latest research and treatment strategies.
David B. Corry, MD. Medicine-Immunology, Allergy and Rheumatology, Baylor College of Medicine
The World Asthma Foundation (WAF), in collaboration with Dr. David Corry, a renowned airway mycosis and severe Asthma specialist at Baylor University, is committed to raising awareness about this critical issue and the underlying mechanisms of severe asthma.
To address this knowledge gap and improve patient outcomes, WAF is hosting an online symposium April 5-6, 2025. This blog post lays the groundwork for the event, which will bring together experts to discuss diagnosing and managing airway mycosis in severe Asthma patients.
By fostering collaboration, the symposium aims to unveil the hidden mechanisms of fungal asthma, including the root fungal cause and empower better understanding and treatment options for patients with severe asthma.
Burden of Airway Mycosis
Misdiagnosis and Underdiagnosis: Airway mycosis often mimics other respiratory illnesses and is difficult to diagnose using standard methods, leading to misdiagnosis and delayed treatment. This can worsen symptoms and hinder overall patient outcomes.
Chronic Illness and Suffering: Airway mycosis can cause debilitating symptoms like chronic cough, wheezing, shortness of breath, and chest pain. It significantly reduces patients’ quality of life.
Economic Costs: The economic burden of airway mycosis is substantial. Direct medical costs associated with treatment and hospitalization are high. Additionally, indirect costs due to lost productivity are significant.
Challenges and Gaps in Knowledge
Incomplete Understanding of Causes: Dr. Corry’s research emphasizes the need for further investigation into the exact mechanisms by which fungi contribute to airway diseases. The complex interplay between fungal exposure, immune response, and airway inflammation remains unclear.
Mechanisms of fungal asthma are incompletely understood. Research into how fungi cause asthma has improved with the discovery of virulence factors such as proteases and candidalysin, but this has yet to translate into new therapies. Newer antifungal agents such as peptoids and many others hold great promise for better management of airway mycosis.
Limited Diagnostic Tools: Current diagnostic methods for airway mycosis are often insensitive and lack specificity. This makes timely and accurate diagnosis difficult.
Silos in Treatment Approaches: A fragmented approach often exists in managing airway mycosis. Improved collaboration between pulmonologists, allergists, immunologists, and infectious disease specialists is essential.
The Way Forward
Raising Awareness: Increased awareness among healthcare professionals and the public is crucial for earlier diagnosis and improved treatment outcomes. The WAF symposium directly addresses this need.
Enhanced Diagnostics: Dr. Corry’s work on culturing techniques offers promise for improved fungal detection. Development of more accurate and specific diagnostic tools remains essential for proper diagnosis of airway mycosis. These methods are open source and inexpensive; the main hindrance is regulatory acceptance of new protocols.
Investment in Research: Further research is required to elucidate the underlying causes of airway mycosis, identify new treatment options, and improve patient management strategies. The World Asthma Foundation symposium can serve as a catalyst for such research collaborations.
Conclusion
Airway mycosis poses a significant but under-recognized burden on patients and healthcare systems. By raising awareness, improving diagnostics, fostering collaboration, and investing in research, we can effectively address the challenges of this complex disease. The World Asthma Foundation symposium serves as a springboard for this critical work.
The World Asthma Foundation (WAF). WAF is a nonprofit organization dedicated to improving the lives of people with asthma through education, research, and advocacy. In this blog post, I want to share with you some exciting findings from a recent study on the microbiome and asthma, published by Spanish researchers in the journal Nutrients.
The microbiome is the collection of microorganisms that live in and on our bodies, such as bacteria, fungi, viruses, and parasites. The microbiome plays an important role in our health and immunity, and can also influence our susceptibility and response to various diseases, including asthma.
Asthma is a chronic inflammatory disease of the airways that affects millions of people worldwide. Asthma can be triggered by different factors, such as allergens, infections, pollution, stress, and diet. Asthma can also have different phenotypes (characteristics), such as allergic or non-allergic, eosinophilic or non-eosinophilic, mild or severe.
What is the microbiome and how does it affect asthma?
The study by Valverde-Molina and García-Marcos reviews the current evidence and challenges on the relationship between the microbiome and asthma, specifically how microbial dysbiosis (an imbalance of the microbial communities in the body) can influence the origins, phenotypes, persistence, and severity of asthma.
How different factors can influence the microbiome and asthma
The study explores how different factors, such as diet, environment, genetics, and infections, can affect the microbiome and asthma, and how modulating the microbiome could be a potential strategy for preventing or treating asthma. The study also reviews the different methods and techniques used to study the microbiome and its interactions with the immune system and the respiratory system.
The gut-lung axis: a key connection between the microbiome and asthma
One of the key points of the study is the importance of the gut-lung axis in the origin and persistence of asthma. The gut-lung axis is the concept that describes how the gut and lung microbiomes communicate with each other through various pathways, such as metabolites, cytokines, antibodies, and immune cells. The gut-lung axis can modulate inflammation and allergic responses in both organs.
The study shows that the process of microbial colonization in the first three years of life is fundamental for health, with the first hundred days of life being critical. Different factors are associated with early microbial dysbiosis, such as caesarean delivery, artificial lactation and antibiotic therapy, among others.
How microbial dysbiosis can lead to different asthma phenotypes and severity
Longitudinal cohort studies on gut and airway microbiome in children have found an association between microbial dysbiosis and asthma at later ages of life. A low ?-diversity (the number of different species) and relative abundance of certain commensal gut bacterial genera in the first year of life are associated with the development of asthma. Gut microbial dysbiosis, with a lower abundance of Phylum Firmicutes (a group of bacteria that includes lactobacilli), could be related with increased risk of asthma.
Upper airway microbial dysbiosis, especially early colonization by Moraxella spp. (a type of bacteria that can cause respiratory infections), is associated with recurrent viral infections and the development of asthma. Moreover, the bacteria in the respiratory system produce metabolites (substances produced by metabolism) that may modify the inception of asthma and its progression.
The role of the lung microbiome in asthma development has yet to be fully elucidated. Nevertheless, the most consistent finding in studies on lung microbiome is the increased bacterial load (the number of bacteria) and the predominance of proteobacteria (a group of bacteria that includes Haemophilus spp. and Moraxella catarrhalis), especially in severe asthma.
Candida albicans: a fungal culprit in asthma development and exacerbation
The study also mentions Candida albicans (a type of fungus that can cause infections) as one of the fungal genera that can affect the gut and lung microbiome and asthma. Candida albicans can trigger inflammation and autoimmune responses in the body. Candida albicans can also induce a Th17 response (a type of immune response) in the gut and lungs. Candida albicans can also increase lung bacterial load and exacerbate airway inflammation.
This study is very relevant to our own research and findings on Candida’s role in inflammation and autoimmune response: implications for severe asthma. We published an article on this topic on our website on October 13th 2021 which features findings from Mayo Clinic researchers who examined how intestinal fungal microbiota affects lung resident memory CD4+ T cells (a type of immune cell) in patients with asthma.
How modulating the microbiome could be a promising strategy for asthma prevention and treatment
We think that these studies complement each other well and provide valuable insights into this important and emerging topic. We believe that understanding the microbiome and its impact on asthma is crucial for developing new and effective strategies for prevention, diagnosis, and treatment of this chronic disease.
Common food dye can trigger inflammatory processes, say university researchers
A recent university study funded by the Canadian Institutes of Health Research reflects that long-term consumption of Allura Red food dye can be a potential trigger of inflammatory bowel diseases (IBDs) and potentially other inflammatory diseases processes as well.
Researchers using experimental animal models of IBD found that continual exposure to Allura Red AC harms gut health and promotes inflammation. Researchers using experimental animal models of IBD found that continual exposure to Allura Red AC harms gut health and promotes inflammation.
‘This further understanding will benefit Asthmatics as well,’ said Alan Gray, Director at the World Asthma Foundation . The human gastrointestinal (GI) tract is home to a diverse ecosystem of microbes, known collectively as the microbiota. Among its many roles, the gut microbiota regulates the immune system and protects against harmful pathogens. In fact, the largest part of the immune system, the gut-associated lymphoid tissue, is found in the gut. This network of immune cells and tissues interacts closely with the gut microbiota, influencing inflammation throughout the body including the lungs.
The dye directly disrupts gut barrier function and increases the production of serotonin, a hormone/neurotransmitter found in the gut, which subsequently alters gut microbiota composition leading to increased susceptibility to colitis.
Khan said Allura Red (also called FD&C Red 40 and Food Red 17), is a common ingredient in candies, soft drinks, dairy products and some cereals. The dye is used to add colour and texture to foodstuffs, often to attract children.
The use of synthetic food dyes such as Allura Red has increased significantly over the last several decades, but there has been little earlier study of these dyes’ effects on gut health. Khan and his team published their findings in Nature Communications. Yun Han (Eric) Kwon, who recently completed PhD in Khan’s laboratory, is first author.
“This study demonstrates significant harmful effects of Allura Red on gut health and identifies gut serotonin as a critical factor mediating these effects. These findings have important implication in the prevention and management of gut inflammation,” said Khan, the study’s senior author, a professor of the Department of Pathology and Molecular Medicine and a principal investigator of Farncombe Family Digestive Health Research Institute.
“What we have found is striking and alarming, as this common synthetic food dye is a possible dietary trigger for IBDs. This research is a significant advance in alerting the public on the potential harms of food dyes that we consume daily,” he said.
“The literature suggests that the consumption of Allura Red also affects certain allergies, immune disorders and behavioural problems in children, such as attention deficit hyperactivity disorder.”
Khan said that IBDs are serious chronic inflammatory conditions of the human bowel that affect millions of people worldwide. While their exact causes are still not fully understood, studies have shown that dysregulated immune responses, genetic factors, gut microbiota imbalances, and environmental factors can trigger these conditions.
In recent years there has been significant progress in identifying susceptibility genes and understanding the role of the immune system and host microbiota in the pathogenesis of IBDs. However, similar advances in defining environmental risk factors have lagged, he said.
Khan said that environmental triggers for IBDs include the typical Western diet, which includes processed fats, red and processed meats, sugar and a lack of fibre. He added that the Western diet and processed food also includes large amounts of various additives and dyes.
He added that the study suggests a link between a commonly used food dye and IBDs and warrants further exploration between food dyes and IBDs at experimental, epidemiological and clinical levels.
World Asthma Foundation” Defeating Asthma Series Uncovers New Hope for Asthma Management
Asthmatics: Our understanding of Asthma and the way we treat it may soon be radically different from what currently exists, due to new research on the human microbiome and how the microbiome affects asthma. Looking at Asthma and Sustainable Healthcare, keeping costs under control while delivering high quality healthcare.
In this interview with Rodney Dietert, PhD Cornell University Professor Emeritus, Health Scientist Head of Translational Science + Education for SEED and the Author of the Human Super-Organism How the Microbiome is Revolutionizing the Pursuit of a Healthy Life we learn about the benefits of Sustainable Healthcare and what we should be thinking about to get there.
Interview on Asthma and Sustainable Healthcare
World Asthma Foundation: You write about the microbiome and sustainable health care. Can you explain why this matters?
Dr. Dietert: I think that recent estimates from CDC and WHO, that global death by these non-communicable diseases like asthma, inflammatory bowel, and the like, it’s not just developed countries but developing countries as well. Is 70-75% of all deaths are from these conditions.
You might note that people live sometimes many decades with these conditions with polypharmacy. Furthermore, if you have one of those, you have a really good chance as you age of having more. That requires additional medications, each one with different side effects, and potential drug interactions can occur.
We think we’re very healthy because of longevity. But we lead a lot of our life in illness and sometimes stressing our caregivers’ system because some of these (conditions) require caregivers as well. There’s a different path. That (the present path) is not, in my mind, a sustainable path.
Testing Sustainable Healthcare
My family are well represented in some of these diseases. We know the trajectory, we’ve lived the trajectory and there’s a different way to go. Once you recognize that it starts with our interaction with the external world, and the microbiome is the interface. It’s what they see: the chemicals, drugs, food first. And what we get is what they’ve dealt with and left behind or metabolized and reacted to.
Control What Can Be Controlled
We can and should control that and it should be integrated so we’re dealing with it like the regenerative agriculture people. Dealing with the soil, the air, the water, the plants, the animals, and us as a continuum of microbial interactions, where we can really have everything be healthy and sustainable.
Reduce Disease Prevalence
If we do that, we’re going to reduce the prevalence of these diseases. The drug companies will find other ways to continue to be profitable in a sustainable way, but we don’t need to be chasing symptoms of some of these diseases but instead cure the disease.
Treating Symptoms Not Causes
Quite frankly, I think I’ve discussed in the book, we’ve cured very few of these diseases. We treat symptoms. In fact, we only treat presenting symptoms. I’ve shown how these diseases are all very much connected as co-morbid factors of each other. A child diagnosed with asthma, we know what kind of diseases are likely to show up in those groups of children with asthma as they age.
In my mind, physicians have yet to deal with that. They actually don’t do things that stop that from happening in a 30, 40, 50-year old when they see a child with asthma. They treat the symptom of the day. That’s a change and a change that would allow us to be much more sustainable in our health and in our medicine that we practice.
Asthma and Sustainable Healthcare, Rodney Dietert PdD
World Asthma Foundation “Defeating Asthma Series uncovers New Hope for Asthma Managementant
Our understanding of Asthma and the way we treat it may soon be radically different from what currently exists, due to new research on the human microbiome and how the microbiome affects asthma.
In this interview with Marie-Claire Arrieta Ph.D, Assistant Professor Depts. of Physiology and Pharmacology & Pediatrics Cumming School of Medicine University of Calgary Health Research Innovation Centre, Calgary, Alberta, Canada we learn that:
A significant proportion of asthmatics have severe asthma that also cannot be controlled easily with the current treatments
The microbiome is not only bacteria just like other ecosystems. Not only bacteria but they’re mix including environmental fungi
The microbiome is full of viruses as well
Interview
World Asthma Foundation: Dr. Arrieta, what prompted your research in this area?
Dr. Arrieta: As you know, asthma has no known cures. A significant proportion of asthmatics have severe asthma that also cannot be controlled easily with the current treatments, so we’re trying to figure out ways of improving both the prevention and the potential therapies for asthma. We also know that asthma has become an epidemic disease in Canada. At least it’s quadrupled in incidence over only 30 years, and we know that it’s mainly environmental factors that are explaining or possibly explaining this really great increase in incidence for asthma.
We’ve come to learn in the past 10 years that the microbiome is implicated. The gut microbiome is this very large community of microbes that we all harbor in our inner guts. However, The vast majority of these studies of the microbiome and asthma have only included bacteria, including studies that I have participated in before. This only provides a part of the view of this vast variety of microbes that we know inhabit this microbial ecosystem.
The microbiome is not only bacteria just like other ecosystems. Not only bacteria but they’re mixed, and they definitely include fungi. We thought that studying the role of fungi would be important because molds and environmental fungi are quite common triggers of asthma attacks in asthmatics, also for people with allergies. This, we thought, may suggest that the fungi in the microbiome, that no one has been studying much before, may be involved in some of the immune education that happens early in life that may later in childhood lead to this uncontrolled inflammation in the airways towards environmental fungi, along with other environmental triggers of asthma. That’s why we wanted to look at fungi.
World Asthma Foundation: Excellent. Great study. I’m most impressed. What are some of the key findings?
Dr. Arrieta: We found by giving specific species or types of fungi and/or bacteria to mice, and we used a specific type of mouse known as the germ-free mouse. These are mice that are kept completely devoid of microbes, so they’re like a blank state that you can associate with microbes in a way that would allow you to then make good conclusions from the experiment.
We found that fungi have a very important role in the way the microbiome establishes early in life. When I say microbiome, now I mean a combination of both bacteria and fungi. We also found that fungi are sensed by the immune system differently than bacteria in a way that they seem to amplify the immune response. For example, we found that mice that were colonized only with fungi were more susceptible to asthma.
World Asthma Foundation: Interesting. Along with that, what were some of the other key findings?
Dr. Arrieta: The story’s definitely developing. This study was certainly a proof of concept, but based on this work as well as others that are starting to look at fungi too, we think that when fungi in the intestine of babies bloom, for example, during an antibiotic treatment, this may change the way the immune system responds to this microbiome that is now higher in proportion with certain fungi. This may also increase the susceptibility to those immune alterations that can later lead to asthma in certain people.
World Asthma Foundation: Interesting. I noticed that you mentioned several references to Candida albicans. How does that fit into the mix?
Dr. Arrieta: We don’t know yet. We chose Candida because it’s a very common yeast in our guts. Virtually everyone would have some candida in their bodies, not just in their guts, but it’s a very common inhabitant. Because of that, we wanted to use a species that was common. We found that Candida certainly can outgrow during antibiotic treatments. It may be one of the species implicated, but we’re not there yet. We’re now trying more species of fungi. In fact, we started a new set of experiments based on an infant clinical study that we just completed that showed us exactly which are the yeast and fungal species that bloom when babies are given antibiotics.
This was an interesting clinical study. We ran it at the emergency department of one of our children’s hospitals where we enrolled babies under six months of age, that for one reason or another had to take an antibiotic. This is a very common occurrence for infants. Then what we did was that we followed the microbiome during this antibiotic treatment, and we were able to identify the most common yeasts that seem to outgrow during the antibiotic treatment. We’re focusing on those, and surprisingly, Candida is not one of those all the time. It seems that, of course, Candida is there, but there’s other fungi that are able to outcompete other ones including Candida. Those are the ones that we’re focusing on now.
World Asthma Foundation:Thank you for that. By outcompete, the suggestion or the inference would be that the imbalance of fungi and bacteria are what’s causing the inflammation process?
Dr. Arrieta: That could be that case. That will be the next step, but as I said, the story is very much developing. I think we’re one of the first ones, but we’re not the only ones interested in studying the fungal component of the microbiome and how it relates to allergies and asthma. I think that in the next couple of years we’re going to learn a lot more.
World Asthma Foundation: Fair enough. What implications are there for asthma? Asthma rates are on the rise. What would you like asthmatics to know about your study?
Dr. Arrieta: For now, because the study is developing, I think what we know for sure is that the gut microbiome during early life is extremely important when it comes to, in general, immune development. Because asthma, of course, is an immune disease, these changes in the gut microbiome can certainly determine a baby’s risk to develop this disease, especially as we now understand in families that have a familial history of asthma as well.
What is important to asthmatics to know? There are certain lifestyle, changes, or behaviors that are now being recommended, including natural birth if, of course, is safe and possible, the use of breast milk over formula if it is possible. One of the things that we’re learning more about is that one of the ways to foster a healthy microbiome early in life is when babies start eating solid foods to make the diet as healthy as possible, the way nutritionists have been asking as to do so for decades now because this will foster a varied microbiome.
World Asthma Foundation: Good point. A fair amount of adult asthmatics suffer from fungal issues relative to lung inflammation and infection. Any thoughts on that?
Dr. Arrieta: There’s a couple of clinical studies, and I wish I remember from the top of my head the name of the drug exactly, that is being tested right now. I’m by no means, involved in this. I have just been reading it with great interest because it is an immune modulator. It’s a biological drug that targets some of the immune mechanisms that we now know recognize fungi. It’ll be really interesting to see now from the point of view of these patients, both children, and adults, that have fungal asthma, if this is really going to change their treatment options because as you know, those asthma tend to be more severe and harder to treat as well.
World Asthma Foundation: What would you like the scientific community to know about your research?
Dr. Arrieta: That within this revolution of studying that microbiome, I think we’re missing out by only focusing on bacteria. There’s a great deal that I have learned from my colleagues in microbial ecology. I am not an ecologist, but I started to partner up with them because of the methods and the concepts, and scientific frameworks that they used to study the microbiome. The microbiome is an ecosystem, and we have experts that have been studying ecosystems for decades before biomedical researchers started to study ecosystems. The inclusion of fungi, I think, will get us more answers. Also, the inclusion of other microorganisms that very few people, if any, are considering right now in the context of asthma research, which are viruses, very popular of course now because we’re under a pandemic. The microbiome is full of viruses and children experience many viral infections during the first year of life or the first two years of life. How does the immune system react to that? How does it get educated? I think that using a broader, more ecologically informed approach to study the microbiome is a lesson that I have learned over the years and I hope that others follow suit too.
World Asthma Foundation “Defeating Asthma Series uncovers New Hope for Asthma Managementant
Asthmatics: Our understanding of Asthma and the way we treat it may soon be radically different from what currently exists, due to new research on the human microbiome and how the microbiome affects asthma.
In the sixth in a series of interviews with Rodney Dietert, PhD Cornell University Professor Emeritus, Health Scientist Head of Translational Science + Education for SEED and the Author of the Human Super-Organism How the Microbiome is Revolutionizing the Pursuit of a Healthy Life we learn about:
Existing evidence clearly demonstrates an association between asthma initiation and the microbiome, both respiratory and gastro-intestinal
Regenerative Agriculture is good for the microbiome
A diet that is not diverse results in a depleted microbiome
People or animals with a depleted microbiome are open to getting some microbiome components from others and the environment around them
Interview
World Asthma Foundation: Dr. Dietert, Can you talk about a) different types of microbiomes, and b) microbiome sharing?
Video interview: Asthma and Microbiome Sharing – Rodney Dietert, Phd
Dr. Dietert: I’ve had an opportunity to lecture at a couple of different conferences. I’ll mention them if you don’t mind. The Quivira Collection – Regenerative Agriculture Conference in Albuquerque and then the Organic and Natural Health Annual Conference was in Florida. You put those two groups together, again, the regenerative agriculture, farmers, ranchers, and scientists doing things in ways that we never envisioned in terms of integration.
They start with the soil, and they start with animals and insects and how you use them together in an ecosystem to really be productive as a rancher or a farmer but to really support the microbiome of soil, of the plants and the diversity of the plants because those are foodstuffs for their production animals. It turns out the more plants that you may have contributing to the diet, the more robust, in a sense, and diversified the production animal is and the phytonutrients that you will gain through the meat or through the milk or through the eggs from that production animal. It is mind-blowing, it is absolutely mind-blowing.
If you don’t mind just a short story, we have examples of that. You have something like the howler monkey in Vietnam, I believe, eats normally in the wild 57 species of plants. In Vietnamese zoos, they eat maybe 12. I forget the exact number but lower double digits. There are some effects on the microbiome. In the US zoos, they eat one plant species. Guess what’s represented in their microbiome which is a very severely degraded microbiome? Their microbiome becomes humanized with the microbes from the animal handlers.
Actually, the same thing happens in our lab rodents, our lab mice, and our lab rats. They are not like wild mice and rats living out in the wild. They are in a very constrained animal handling setting, and they actually acquire the animal technicians’ microbes to some extent. Investigators working on the immune system, for example, told me, “We were doing these great experiments everything was working and then they didn’t.” Turned out there was a new building built, and they moved their animals over there, or they changed all their staff in the animal facility.
It’s a lesson for us that if you’re in a depleted state, you will pick up microbes from your surroundings. One other point about that that’s interesting is that I talked about non-communicable diseases, NCDs. If I wrote that book now, and I am planning a follow-up book, I wouldn’t use that acronym because a lot of people ask me, they say, “I have asthma or I have Crohn’s. We’re not genetically related but my spouse living in the same household, eating the same food, same air, also developed it later on. Is there any chance these things are actually slightly communicable?” The answer is, more and more, yes, slightly communicable is probably right.
If you get a really depleted microbiome state like you’ve had Lyme disease or something, you have multiple extensive rounds of antibiotics and your household has a microbiome that has — you can argue which came first but — is an asthma microbiome or is a Crohn’s or something, psoriasis, yes, you are open to donation. It could be from your home or hotel room or an airplane but you’re open to something getting in. There are tipping points where there’s some evidence that it’s not like a regular pandemic but to some extent, to say it’s non-communicable is not quite right because we’re sharing microbes all the time.
World Asthma Foundation: Dr. Dietert, we certainly thank you for your time, all that you do for the microbiome and the community. Good afternoon, and thanks again.
Dr. Dietert: Well, and thank you for all you do with the World Asthma foundation, Bill. Pleasure.
In this fifth in a series of interviews with Rodney Dietert PhD, he talks about communication between the gut and lung. Dr. Dietert is Cornell University Professor Emeritus, Health Scientist Head of Translational Science + Education for SEED and the Author of the Human Super-Organism How the Microbiome is Revolutionizing the Pursuit of a Healthy Life we learn about:
* The Gut and lung communication and its relationship to Asthma
World Asthma Foundation “Defeating Asthma Series uncovers New Hope for Asthma Managementant
Asthmatics: Our understanding of Asthma and the way we treat it may soon be radically different from what currently exists, due to new research on the human microbiome and how the microbiome affects asthma.
Interview
World Asthma Foundation: Research into the Microbiome and its relationship to health has improved significantly in the last few years. For example, we now know about the relationship between the gut and health. We’ve also learned about communication between the gut and the lung and the impact on Asthma. Dr. Dietert, so there’s some crosstalk, right?
Video interview: Asthma Connection to Gut and Lung Cross Talk – Rodney Dietert, PhD
Dr. Dietert: Tremendous crosstalk, absolutely tremendous. You’re correct that if you’re looking at endpoints, something like risk of asthma or management of asthma, then you really, at a minimum, are going to focus both on the respiratory system microbiome and the gut microbiome. That’s not necessarily the exclusion of others but those two are really important. Just like the gut microbiome can affect the brain, it can affect behavior, mood. You don’t need lots of hardcore meds as an antidepressant when you’ve got the solution sitting right in your gut in terms of the microbiome.
With the respiratory system, you’ve got both the local microbes being extremely important but you have crosstalk, you have chemical interactions that are originating in the gut that are affecting the respiratory system as well.
World Asthma Foundation: Dr. Dietert, we certainly thank you for your time, all that you do for the microbiome and the community. Good afternoon, and thanks again.
Dr. Dietert: Well, and thank you for all you do with the World Asthma foundation, Bill. Pleasure.
Defeating Asthma Series uncovers New Hope for Asthma Managementant
In this fourth in a series of interviews with Rodney Dietert, PhD Cornell University Professor Emeritus, Health Scientist Head of Translational Science + Education for SEED and the Author of the Human Super-Organism How the Microbiome is Revolutionizing the Pursuit of a Healthy Life we learn about:
* Replacing replacing missing microbes
World Asthma Foundation: Dr. Dietert can we replace missing microbes?
Dr. Dietert: There are products available and we have used a product that is a missing skin microbe. It’s very important in certain metabolic pathways that actually help provide health benefits that are beyond the skin.
Video: Can we replace missing microbes? – Rodney Dietert Ph.D.
That was one that basically was recovered in a very interesting way that involved essentially marriages between some indigenous people and others that were westernized and the microbe being able to not necessarily be removed from a remote location but being able to be a part of what we would call genetically an F1.
There are opportunities to retrieve some missing microbes. I think Dr. Blaser and his wife have done incredible work by the way as well, very much attuned and will have a lot to offer on what’s missing and where is it and can it be retrieved. I think the answer is yes. There are commercial products and we’ve actually used some of them that are the missing microbes.
It’s important to recognize that some of the indigenous peoples that have not had the same environmental experiences that we’ve had, and the same contact with modernization have microbes that are exceptionally important for health are helping prevent obesity and asthma and diabetes in those populations. Those microbes are really the protectors.
Yes, I think that reintroducing those to the extent it is possible is an extremely worthwhile effort.
I would point out that it’s a fragile situation because I think from Dr. Blaser and his wife’s work, you will learn that the indigenous populations in South America if they go into the urban areas, if their children go into the urban areas, start adopting the diet and lifestyle there, it takes no time at all for them to acquire the same set of diseases that we see so prevalent here.
World Asthma Foundation: With that, Dr. Dietert, we certainly thank you for your time, all that you do for the microbiome and the community. Good afternoon, and thanks again.
Dr. Dietert: Well, and thank you for all you do with the World Asthma foundation, Bill. Pleasure.
Defeating Asthma Series uncovers New Hope for Asthma Management
In this interview with Justin L. Sonnenburg PhD, Associate Professor of Microbiology and Immunology at Stanford University, we learn about:
* Testing for Microbes within the Microbiome
* That we’re in the early stages of our understanding of the Microbiome
* Research that still needs to be done
Our understanding of Asthma and the way we treat it may soon be radically different from what currently exists, due to new research on the human microbiome and how the microbiome affects asthma.
“Diseases largely driven by inflammation and an altered immune system. If we start to take our gut microbiota into account, as we live our life, as we make medical decisions, eat different foods and potentially even eventually reintroduce some of these lost microbes, how profound can the impact be on our health?” Justin L. Sonnenburg Ph.D
Interview
World Asthma Foundation: Dr. Sonnenburg, can we test for what’s in the microbiome?
Video Interview Can we test for whats in the Microbiome? – Justin L. Sonnenburg PhD
Dr. Justin L. Sonnenburg: On an individual level, there are companies that offer testing for the different species to give you the composition of what’s in your microbiome. I can’t speak to the validity of any of these companies, but there are commercial entities out there that will provide a profile for individuals.
World Asthma Foundation: Thanks. Do you know if it’s specific? For example, research reflects that Bifidobacterium breve and Lactobacillus specifically have been targeted. I’m not a hundred percent sure if it’s inflammation or infection or both, it seems to be successful. The question is, can we test for those specific bacteria?
Dr. Justin L. Sonnenburg: There are targeted tests out there for specific bacteria that where we think given the species may be of interest. Of course, this is most famous for infectious agents. If you want to go in and see if you have Clostridium difficile or salmonella or something like that, there are specific targeted tests. These are less common for the good guys in our gut. I think part of the reason is we still don’t have a great understanding of what the good guys are.
There are studies out there that indicate certain associated with health States are associated with being able to fight off specific problems.
In general, quite often what’s found for one population when surveyed in an independent population doesn’t necessarily hold up.
There’s just extreme variability in the gut microbiome. I think as much as we know about the field is still how fundamental this community is to our health, we’re still at a really early stage of understanding what is healthy and also coming to grips with the fact that there is no single definition of healthy, that healthy really depends on the individual, the context, and many other factors.
World Asthma Foundation: It’s a complex issue and relatively emerging, right?
Dr. Justin L. Sonnenburg: Exactly. A lot of research still needs to be done.
World Asthma Foundation: Thank you everything that you do on a daily basis for the gut microbiome, certainly for your teachings and your writings and for your time today. Appreciate it.
Dr. Justin L. Sonnenburg: Wonderful being with you. Thanks so much.
